Spots Global Cancer Trial Database for muscle invasive bladder cancer
Every month we try and update this database with for muscle invasive bladder cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer | NCT04053101 | Muscle Invasive... | PET CT | 18 Years - | Institut Bergonié | |
| Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma | NCT04730219 | Muscle Invasive... Urothelial Carc... | Tislelizumab Nab paclitaxel | 18 Years - | Tianjin Medical University Second Hospital | |
| Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer | NCT04909775 | Muscle-Invasive... | Tislelizumab Cisplatin Gemcitabine | 18 Years - 75 Years | Ruijin Hospital | |
| Robotic Radical Cystectomy Outcomes | NCT04900558 | Bladder Cancer Muscle-Invasive... Oncology Recurrence Surgery | Radical Cystect... | 18 Years - | University of Florence | |
| BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy | NCT03294304 | Muscle Invasive... | Nivolumab Cisplatin Gemcitabine | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer | NCT05241340 | Urothelial Carc... | Sasanlimab Stereotactic Bo... Radical Cystect... | 18 Years - | The Methodist Hospital Research Institute | |
| Cadonilimab Plus Nab-Paclitaxel for Recurrent or Metastatic Muscle Invasive Bladder Cancer | NCT06009848 | Bladder Cancer | Cadonilimab | 18 Years - | Tianjin Medical University Second Hospital | |
| Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | NCT03397394 | Bladder Cancer Urothelial Carc... Metastatic Urot... Renal Pelvis Ca... Ureter Carcinom... Urinary Bladder... Urethra Carcino... Muscle Invasive... | Rucaparib | 18 Years - | pharmaand GmbH | |
| Outcome of Perioperative Immune Enhancing Nutrition in Patients Undergoing Radical Cystectomy | NCT05822518 | Cancer, Bladder Cystostomy; Com... | Neo-mune powder... Dipeptiven solu... | - | Menoufia University | |
| Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer | NCT04101812 | Muscle Invasive... | pegylated lipos... PD-1 | 18 Years - 75 Years | Tianjin Medical University Second Hospital | |
| Robotic Radical Cystectomy Outcomes | NCT04900558 | Bladder Cancer Muscle-Invasive... Oncology Recurrence Surgery | Radical Cystect... | 18 Years - | University of Florence | |
| Basal Like Bladder Cancer : Signature and Therapeutic | NCT02648100 | Muscle Invasive... Molecular Taxon... | biomarker study | 18 Years - 70 Years | Assistance Publique - Hôpitaux de Paris | |
| Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer | NCT04053101 | Muscle Invasive... | PET CT | 18 Years - | Institut Bergonié | |
| Dose Dense MVAC for Muscle Invasive Bladder Cancer | NCT01031420 | Muscle Invasive... High Risk Uroth... | single arm dose... | 18 Years - | Fox Chase Cancer Center | |
| RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC | NCT05979740 | Muscle Invasive... HER2 Expression Radiotherapy PD-1 Antibody-drug C... | Disitamab Vedot... | 18 Years - | RenJi Hospital | |
| Clinical Performance Evaluation of the C2i Test | NCT05860543 | Muscle Invasive... | C2i-WGS-MRD Tes... | 22 Years - | University of Texas Southwestern Medical Center | |
| BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy | NCT03294304 | Muscle Invasive... | Nivolumab Cisplatin Gemcitabine | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC | NCT05979740 | Muscle Invasive... HER2 Expression Radiotherapy PD-1 Antibody-drug C... | Disitamab Vedot... | 18 Years - | RenJi Hospital | |
| A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer | NCT03288545 | Carcinoma, Tran... Urinary Bladder... Urologic Neopla... Renal Pelvis Ne... Urothelial Canc... Ureteral Neopla... Urethral Neopla... | enfortumab vedo... pembrolizumab cisplatin carboplatin gemcitabine | 18 Years - | Astellas Pharma Inc | |
| Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma | NCT04047693 | Muscle Invasive... Urothelial Carc... Neoadjuvant Che... | dose dense MVAC... | 18 Years - | Pusan National University Yangsan Hospital | |
| Assessement of the Concordance of Genomic Alterations Between Urine and Tissue in High-Risk NMIBC Patients | NCT04412070 | Bladder Cancer | 18 Years - | Hopital Foch | ||
| RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC | NCT05979740 | Muscle Invasive... HER2 Expression Radiotherapy PD-1 Antibody-drug C... | Disitamab Vedot... | 18 Years - | RenJi Hospital | |
| Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC | NCT03732677 | Muscle Invasive... | Durvalumab Cisplatin Gemcitabine | 18 Years - 130 Years | AstraZeneca | |
| Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy | NCT03171493 | Urothelial Carc... | MV-NIS | 18 Years - | Vyriad, Inc. | |
| To Better Understand the Most Important Factors for Patients When They Decide on the Type of Treatment They Receive for Muscle Invasive Bladder Cancer (MIBC). | NCT05236218 | Muscle Invasive... Surgery Sexual Wellbein... Patient Satisfa... Patient Prefere... | Discrete Choice... Semi-Structured... | 18 Years - | King's College London | |
| A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer | NCT04813107 | Muscle Invasive... | APL-1202 in com... Tislelizumab al... | 18 Years - | Jiangsu Yahong Meditech Co., Ltd aka Asieris | |
| Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging | NCT02203136 | Bladder Cancer | Tissue Biopsy Magnetic Resona... | - | M.D. Anderson Cancer Center | |
| Evaluation of NanoDoce® in Participants With Urothelial Carcinoma | NCT03636256 | Bladder Cancer Urothelial Carc... Urinary Bladder... Urinary Bladder... Urogenital Neop... Urologic Neopla... Urologic Cancer Malignant Tumor... Cancer of the B... | NanoDoce (direc... NanoDoce (intra... Institutional S... NanoDoce (intra... | 18 Years - | NanOlogy, LLC | |
| Assessement of the Concordance of Genomic Alterations Between Urine and Tissue in High-Risk NMIBC Patients | NCT04412070 | Bladder Cancer | 18 Years - | Hopital Foch | ||
| BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy | NCT03294304 | Muscle Invasive... | Nivolumab Cisplatin Gemcitabine | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer | NCT05241340 | Urothelial Carc... | Sasanlimab Stereotactic Bo... Radical Cystect... | 18 Years - | The Methodist Hospital Research Institute | |
| A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) | NCT03773666 | Muscle Invasive... | Durvalumab Oleclumab | 18 Years - | Dana-Farber Cancer Institute | |
| Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer | NCT04053101 | Muscle Invasive... | PET CT | 18 Years - | Institut Bergonié | |
| BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy | NCT03294304 | Muscle Invasive... | Nivolumab Cisplatin Gemcitabine | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder | NCT02662309 | Bladder Cancer | MPDL3280A | 18 Years - | Queen Mary University of London | |
| Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging | NCT02203136 | Bladder Cancer | Tissue Biopsy Magnetic Resona... | - | M.D. Anderson Cancer Center | |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer | NCT02546661 | Muscle Invasive... | AZD4547 MEDI4736 Olaparib AZD1775 Vistusertib AZD9150 Selumetinib | 18 Years - 130 Years | AstraZeneca | |
| Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma | NCT04730219 | Muscle Invasive... Urothelial Carc... | Tislelizumab Nab paclitaxel | 18 Years - | Tianjin Medical University Second Hospital | |
| Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin | NCT04960709 | Muscle Invasive... | Durvalumab Tremelimumab Enfortumab Vedo... Radical Cystect... | 18 Years - 130 Years | AstraZeneca | |
| Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer | NCT02716896 | Muscle Invasive... | Radiation and c... Radical cystect... | 18 Years - 89 Years | The University of Texas Health Science Center at San Antonio | |
| Clinical Performance Evaluation of the C2i Test | NCT05860543 | Muscle Invasive... | C2i-WGS-MRD Tes... | 22 Years - | University of Texas Southwestern Medical Center | |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer | NCT02546661 | Muscle Invasive... | AZD4547 MEDI4736 Olaparib AZD1775 Vistusertib AZD9150 Selumetinib | 18 Years - 130 Years | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
